Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation

Selective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinica...

Full description

Bibliographic Details
Main Authors:	Billie Radovic, Caitlyn Cummings, Lubaina Presswala, Ronald Rosen
Format:	Article
Language:	English
Published:	Elsevier 2020-12-01
Series:	Current Problems in Cancer: Case Reports
Subjects:	Adjuvant hormonal therapy Breast cancer Diabetes Tamoxifen Hyperglycemic hyperosmolar state
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666621920300077

id	doaj-ab47d38289084d0684915cd9752f90b8
record_format	Article
spelling	doaj-ab47d38289084d0684915cd9752f90b82021-09-03T04:47:58ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192020-12-011100007Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammationBillie Radovic0Caitlyn Cummings1Lubaina Presswala2Ronald Rosen3Department of Medicine, Long Island Jewish Medical Center, 755 North Broadway, Suite 100, Sleepy Hollow, Hyde Park, New York, United States; Corresponding author.Department of Pharmacy, Long Island Jewish Medical Center, New Hyde Park, New York, United StatesDivision of Endocrinology, Diabetes and Metabolism, Long Island Jewish Medical Center, New Hyde Park, New York, United States; Assistant Professor of Medicine, Zucker School of Medicine, Hofstra University, Hempstead, New York, United StatesDepartment of Medicine, Chief Emeritus, Long Island Jewish Medical Center, New Hyde Park, New York, United States; Assistant Professor of Medicine, Zucker School of Medicine, Hofstra University, Hempstead, New York, United StatesSelective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinical case, one patient presented with hyperosmolar hyperglycemic state two months after starting tamoxifen for male breast cancer. Discontinuation of tamoxifen resulted in decreased hemoglobin A1c levels back to baseline and rebound of C- peptide levels.http://www.sciencedirect.com/science/article/pii/S2666621920300077Adjuvant hormonal therapyBreast cancerDiabetesTamoxifenHyperglycemic hyperosmolar state
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Billie Radovic Caitlyn Cummings Lubaina Presswala Ronald Rosen
spellingShingle	Billie Radovic Caitlyn Cummings Lubaina Presswala Ronald Rosen Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation Current Problems in Cancer: Case Reports Adjuvant hormonal therapy Breast cancer Diabetes Tamoxifen Hyperglycemic hyperosmolar state
author_facet	Billie Radovic Caitlyn Cummings Lubaina Presswala Ronald Rosen
author_sort	Billie Radovic
title	Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
title_short	Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
title_full	Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
title_fullStr	Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
title_full_unstemmed	Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
title_sort	tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation
publisher	Elsevier
series	Current Problems in Cancer: Case Reports
issn	2666-6219
publishDate	2020-12-01
description	Selective estrogen receptor modulators, such as tamoxifen, have been used for many years to reduce the recurrence of breast cancer. There is limited data on tamoxifen use in males with breast cancer. Hyperglycemia or risk of diabetes is not listed on the package insert for tamoxifen. In this clinical case, one patient presented with hyperosmolar hyperglycemic state two months after starting tamoxifen for male breast cancer. Discontinuation of tamoxifen resulted in decreased hemoglobin A1c levels back to baseline and rebound of C- peptide levels.
topic	Adjuvant hormonal therapy Breast cancer Diabetes Tamoxifen Hyperglycemic hyperosmolar state
url	http://www.sciencedirect.com/science/article/pii/S2666621920300077
work_keys_str_mv	AT billieradovic tamoxifeninducedhyperosmolarhyperglycemicstatesecondarytosuspectedpancreaticbetacellinflammation AT caitlyncummings tamoxifeninducedhyperosmolarhyperglycemicstatesecondarytosuspectedpancreaticbetacellinflammation AT lubainapresswala tamoxifeninducedhyperosmolarhyperglycemicstatesecondarytosuspectedpancreaticbetacellinflammation AT ronaldrosen tamoxifeninducedhyperosmolarhyperglycemicstatesecondarytosuspectedpancreaticbetacellinflammation
_version_	1717817872824139776

Tamoxifen-induced hyperosmolar hyperglycemic state secondary to suspected pancreatic beta cell inflammation

Similar Items